Fig. 2: CD27 gene expression associated with immune cell infiltration levels and immune-related pathways. | npj Precision Oncology

Fig. 2: CD27 gene expression associated with immune cell infiltration levels and immune-related pathways.

From: CD27 expression is a clinically accessible biomarker for predicting immunotherapy response in melanoma

Fig. 2: CD27 gene expression associated with immune cell infiltration levels and immune-related pathways.The alternative text for this image may have been generated using AI.

A Correlations between CD27 mRNA expression and tumor purity, as well as immune cell infiltration levels, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells in metastatic SKCM. B Box plot showing differences in absolute proportions of immune cells in the tumor microenvironment between high and low CD27 mRNA expression groups. C Box plot displaying differences in estimated leukocyte proportions based on methylation data between high and low CD27 expression groups. D Box plot showing the proportion of TILs, evaluated from pathological images, in high and low CD27 mRNA expression groups. E GSEA plot illustrating enriched hallmark gene sets and pathways in the high CD27 mRNA expression group (FDR < 0.05). F Heatmap displaying the expression of four immune therapy-related signature gene sets, including IFNγ-6, IFNγ expanded immune 18, effector T-cell and IFNγ/effector T-cell. G–J Box plots of gene set enrichment scores of IFNγ-6 (G), IFNγ expanded immune 18 (H), effector T-cell (I) and IFNγ/effector T-cell (J) in high and low CD27 mRNA expression groups of metastatic melanoma. *p < 0.05, **p < 0.01, ****p < 0.0001; ns, no significance.

Back to article page